Market research
VIVIMEDLAB.NSE Vivimed Labs Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 500M
- P/E ratio
- Not available
- Analyst target
- 134
- Dividend yield
- Not available
- Beta
- 0.82
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE526G01021
- Market cap
- 500M
- P/E ratio
- Not available
- Analyst target
- 134
- Dividend yield
- Not available
- Beta
- 0.82
About
About Vivimed Labs Limited
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also exports its products. The company was incorporated in 1988 and is based in Hyderabad, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VIVIMEDLAB.NSE discussion.
5 years, 5 months ago
Vivimed Labs Limited is currently in a long term uptrend where the price is trading 25.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Basic Materials sector with a price to sales ratio of 0.1.
Vivimed Labs Limited's total revenue rose by 40.6% to $3B since the same quarter in the previous year.
Its net income has dropped by 54.5% to $-495M since the same quarter in the previous year.
Finally, its free cash flow grew by 127.4% to $824M since the same quarter in the previous year.
Based on the above factors, Vivimed Labs Limited gets an overall score of 4/5.